Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00544115 · OUTCOME

Two-year Overall Survival

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders · Source last updated 2026-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of survival probability
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years post transplant

What was measured

Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.

Analysis population: 1 subject in Regimen II did not have transplant.

Groups in this outcome

Regimen I

Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1. cyclophosphamide cyclosporine methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation

Regimen II

Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2. busulfan cyclophosphamide cyclosporine methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Regimen III

Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3. cyclosporine etoposide methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation

Regimen IV

Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2. cyclosporine fludarabine phosphate melphalan methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Regimen V

Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0. cyclosporine fludarabine phosphate methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation

Regimen VI

Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2. busulfan cyclosporine fludarabine phosphate methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen I62
Regimen II16
Regimen III130
Regimen IV4
Regimen V40
Regimen VI2

Reported measurements

Source class 1
Values in percentage of survival probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen I58Not reported4569Not reported
Regimen II50Not reported2571Not reported
Regimen III54Not reported4562Not reported
Regimen IV50Not reported684Not reported
Regimen V38Not reported2352Not reported
Regimen VI50Not reported0.191Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        45
        upper Limit
        69
        value
        58
      2. group Id
        OG001
        lower Limit
        25
        upper Limit
        71
        value
        50
      3. group Id
        OG002
        lower Limit
        45
        upper Limit
        62
        value
        54
      4. group Id
        OG003
        lower Limit
        6
        upper Limit
        84
        value
        50
      5. group Id
        OG004
        lower Limit
        23
        upper Limit
        52
        value
        38
      6. group Id
        OG005
        lower Limit
        0.1
        upper Limit
        91
        value
        50
denoms
  1. counts
    1. group Id
      OG000
      value
      62
    2. group Id
      OG001
      value
      16
    3. group Id
      OG002
      value
      130
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      40
    6. group Id
      OG005
      value
      2
    units
    Participants
description
Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1. cyclophosphamide cyclosporine methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation
    id
    OG000
    title
    Regimen I
  2. description
    Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2. busulfan cyclophosphamide cyclosporine methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation
    id
    OG001
    title
    Regimen II
  3. description
    Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3. cyclosporine etoposide methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation
    id
    OG002
    title
    Regimen III
  4. description
    Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2. cyclosporine fludarabine phosphate melphalan methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation
    id
    OG003
    title
    Regimen IV
  5. description
    Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0. cyclosporine fludarabine phosphate methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation
    id
    OG004
    title
    Regimen V
  6. description
    Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2. busulfan cyclosporine fludarabine phosphate methotrexate mycophenolate mofetil sirolimus tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation
    id
    OG005
    title
    Regimen VI
param Type
NUMBER
population Description
1 subject in Regimen II did not have transplant.
reporting Status
POSTED
time Frame
Up to 2 years post transplant
title
Two-year Overall Survival
type
SECONDARY
unit Of Measure
percentage of survival probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice